RetinArt | Clinical biomarker for arterial hypertension based on micro-vascular retinal imaging

Summary
The RetinArt project addresses a major public health issue: cardiovascular (CV) events, which are the leading cause of death in the world. The overall project objective is to validate the arteriolar wall-to-lumen ratio (AWLR), a clinical biomarker of the alterations caused by arterial hypertension (AHT) in small arteries. The clinical validation is expected to prove that assessments of the AWLR enable earlier detection of damage caused by AHT, better prediction of CV risk, and more effective adaptation of AHT therapy to patient.
To measure the AWLR biomarker, Imagine Eyes has developed a new retinal imaging system that uses the eye as a window to the microcirculatory system. This instrumentation provides unparalleled microscopic resolution thanks to a breakthrough adaptive optics technology derived from astrophysics. It enables clinicians, for the first time, to directly visualize the microscopic walls of retinal arterioles and quantify the AWLR using automated segmentation software. The examination procedure is totally non invasive and its reliability has been successfully tested with AHT patients in a hospital environment.
The phase 1 of the RetinArt project is a feasibility study that aims at establishing the methodological and economic validity of the proposed clinical validation, and at planning its future execution. The main deliverables expected from phase 1 are a validation plan and a detailed business plan. These outcomes are essential milestones in the translation of Imagine Eyes technology to a new standard that will help reduce the risk of serious complications in wide numbers of AHT patients.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/652542
Start date: 01-10-2014
End date: 31-03-2015
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

The RetinArt project addresses a major public health issue: cardiovascular (CV) events, which are the leading cause of death in the world. The overall project objective is to validate the arteriolar wall-to-lumen ratio (AWLR), a clinical biomarker of the alterations caused by arterial hypertension (AHT) in small arteries. The clinical validation is expected to prove that assessments of the AWLR enable earlier detection of damage caused by AHT, better prediction of CV risk, and more effective adaptation of AHT therapy to patient.
To measure the AWLR biomarker, Imagine Eyes has developed a new retinal imaging system that uses the eye as a window to the microcirculatory system. This instrumentation provides unparalleled microscopic resolution thanks to a breakthrough adaptive optics technology derived from astrophysics. It enables clinicians, for the first time, to directly visualize the microscopic walls of retinal arterioles and quantify the AWLR using automated segmentation software. The examination procedure is totally non invasive and its reliability has been successfully tested with AHT patients in a hospital environment.
The phase 1 of the RetinArt project is a feasibility study that aims at establishing the methodological and economic validity of the proposed clinical validation, and at planning its future execution. The main deliverables expected from phase 1 are a validation plan and a detailed business plan. These outcomes are essential milestones in the translation of Imagine Eyes technology to a new standard that will help reduce the risk of serious complications in wide numbers of AHT patients.

Status

CLOSED

Call topic

PHC-12-2014-1

Update Date

26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.1. Mainstreaming SME support, especially through a dedicated instrument
H2020-SMEINST-1-2014
PHC-12-2014-1 Clinical research for the validation of biomarkers and/or diagnostic medical devices
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.0. Cross-cutting call topics
H2020-SMEINST-1-2014
PHC-12-2014-1 Clinical research for the validation of biomarkers and/or diagnostic medical devices
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-1-2014
PHC-12-2014-1 Clinical research for the validation of biomarkers and/or diagnostic medical devices